Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

详细信息    查看全文

• 作者：Fermin M. Sá ; nchez-Guijo^a ; Soledad Durá ; n^b ; Josefina Galende^c ; Concepci&#xf3 ; n Boqué ; ^d ; José ; B. Nieto^e ; Josep Balanzat^f ; Antonio Gracia^g ; Isabel Garcí ; a^h ; Carmen Avellaneda-Molinaⁱ ; Marí ; a-Victoria Moreno^j ; Elisa Lu&#xf1 ; o-Fernandez^k ; Mar Hermosilla^l ; José ; Manuel Sanchez-Varela^m ; Ana Diosⁿ ; Pilar L&#xf3 ; pez-Garrido^o ; Pilar Giraldo^p ; Joan Bargay^q ; José ; Marí ; a Domingo^r ; Alfonso Soler^s ; Ram&#xf3 ; n Salinas^t ; Maria-Consuelo del Ca&#xf1 ; izo^a ; ^{concarol@usal.es"" rel=""nofollow}
• 关键词：Chronic myeloid leukemia ; Elderly ; Imatinib
• 刊名：Leukemia Research
• 出版年：2011
• 出版时间：September 2011
• 年：2011
• 卷：35
• 期：9
• 页码：1184-1187
• 全文大小：264 K

文摘

Imatinib mesylate (IM) is the treatment of choice in patients with newly diagnosed chronic myeloid leukemia (CML), irrespectively of their age. Nevertheless, information regarding tolerability and responses in advanced-age patients, a subgroup in which co-morbidities and other factors may influence outcome, is scarce, since they were excluded from most clinical trials. In this observational study (ELDERGLI), information regarding demographics, concomitant medication, physical examination, performance status, hemogram, biochemistry, hematologic, cytogenetic and molecular responses, time to progression, adverse events (AE) and severe adverse events (SAE) were prospectively recorded in a series of 36 elderly patients with CML, with a median age of 76.6 years. Most patients had cardiovascular co-morbidities, especially hypertension. Regarding IM toxicity, around one third of patients required treatment interruptions because of adverse events, especially hematologic toxicity (66 % of cases that needed dose interruptions). When analyzing non hematologic adverse events, the most frequent ones were superficial edemas and GI symptoms. Of note, 9 of patients experienced an infection episode during the follow-up, and 4 were diagnosed during the study period of another type of cancer. Finally, cardiovascular events were reported in 7 patients, most of them with prior cardiovascular risk factors. Regarding responses, after 12 months of imatinib therapy, the rate of complete hematologic response (CHR), complete cytogenetic response (CCyR) and major molecular response (MMolR) were 89 % , 72 % and 55 % respectively. In summary, IM display, in advanced-age patients with chronic phase CML, an efficacy and safety profile comparable to younger patients.